These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 16870521)

  • 21. Protective immunity against influenza H5N1 virus challenge in mice by intranasal co-administration of baculovirus surface-displayed HA and recombinant CTB as an adjuvant.
    Prabakaran M; Velumani S; He F; Karuppannan AK; Geng GY; Yin LK; Kwang J
    Virology; 2008 Oct; 380(2):412-20. PubMed ID: 18786689
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy of inactivated vaccines against H5N1 avian influenza infection in ducks.
    Middleton D; Bingham J; Selleck P; Lowther S; Gleeson L; Lehrbach P; Robinson S; Rodenberg J; Kumar M; Andrew M
    Virology; 2007 Mar; 359(1):66-71. PubMed ID: 17028058
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inactivated and adjuvanted whole-virion clade 2.3.4 H5N1 pre-pandemic influenza vaccine possesses broad protective efficacy against infection by heterologous clades of highly pathogenic H5N1 avian influenza virus in mice.
    Harada Y; Ninomiya-Mori A; Takahashi Y; Shirakura M; Kishida N; Kageyama T; Tada Y; Tashiro M; Odagiri T
    Vaccine; 2011 Oct; 29(46):8330-7. PubMed ID: 21911027
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pandemic H5N1 influenza vaccine development: an update.
    El Sahly HM; Keitel WA
    Expert Rev Vaccines; 2008 Mar; 7(2):241-7. PubMed ID: 18324892
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of the potency, optimal antigen level and lasting immunity of inactivated avian influenza vaccine prepared from H5N1 virus.
    Sasaki T; Isoda N; Soda K; Sakamoto R; Saijo K; Hagiwara J; Kokumai N; Ohgitani T; Imamura T; Sawata A; Lin Z; Sakoda Y; Kida H
    Jpn J Vet Res; 2009 Feb; 56(4):189-98. PubMed ID: 19358446
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of protection against H5N1 influenza virus in mouse offspring provided by maternal vaccination with HA DNA and inactivated vaccine.
    Zhang F; Fang F; Chang H; Peng B; Wu J; Chen J; Wang H; Chen Z
    Arch Virol; 2013 Jun; 158(6):1253-65. PubMed ID: 23385327
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety, immunogenicity and efficacy of poxvirus-based vector vaccines expressing the haemagglutinin gene of a highly pathogenic H5N1 avian influenza virus in pigs.
    Kyriakis CS; De Vleeschauwer A; Barbé F; Bublot M; Van Reeth K
    Vaccine; 2009 Apr; 27(16):2258-64. PubMed ID: 19428840
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of the cellular immune responses induced by a non-adjuvanted inactivated whole virus A/H5N1/VN/1203 pandemic influenza vaccine in humans.
    Crowe BA; Brühl P; Gerencer M; Schwendinger MG; Pilz A; Kistner O; Koelling-Schlebusch K; Aichinger G; Singer J; Zeitlinger M; Müller M; Ehrlich H; Barrett PN
    Vaccine; 2010 Dec; 29(2):166-73. PubMed ID: 21055500
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inactivated influenza H5N1 whole-virus vaccine with aluminum adjuvant induces homologous and heterologous protective immunities against lethal challenge with highly pathogenic H5N1 avian influenza viruses in a mouse model.
    Ninomiya A; Imai M; Tashiro M; Odagiri T
    Vaccine; 2007 May; 25(18):3554-60. PubMed ID: 17293015
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prospecting the influenza hemagglutinin to develop universal vaccines.
    Donis RO; Cox NJ
    Clin Infect Dis; 2011 Apr; 52(8):1010-2. PubMed ID: 21460315
    [No Abstract]   [Full Text] [Related]  

  • 31. The Madin-Darby canine kidney cell culture derived influenza A/H5N1 vaccine: a phase I trial in Taiwan.
    Pan SC; Kung HC; Kao TM; Wu H; Dong SX; Hu MH; Chou AH; Chong P; Hsieh SM; Chang SC
    J Microbiol Immunol Infect; 2013 Dec; 46(6):448-55. PubMed ID: 23022464
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparative efficacy of North American and antigenically matched reverse genetics derived H5N9 DIVA marker vaccines against highly pathogenic Asian H5N1 avian influenza viruses in chickens.
    Jadhao SJ; Lee CW; Sylte M; Suarez DL
    Vaccine; 2009 Oct; 27(44):6247-60. PubMed ID: 19686695
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunization against influenza: comparison of various topical and parenteral regimens containing inactivated and/or live attenuated vaccines in healthy adults.
    Keitel WA; Cate TR; Nino D; Huggins LL; Six HR; Quarles JM; Couch RB
    J Infect Dis; 2001 Jan; 183(2):329-332. PubMed ID: 11110645
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [H5N1: vaccine solutions for humans and other animals].
    Durand MP
    Bull Acad Natl Med; 2006; 190(4-5):963-72. PubMed ID: 17195620
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A pandemic influenza vaccine in India: from strain to sale within 12 months.
    Dhere R; Yeolekar L; Kulkarni P; Menon R; Vaidya V; Ganguly M; Tyagi P; Barde P; Jadhav S
    Vaccine; 2011 Jul; 29 Suppl 1():A16-21. PubMed ID: 21684421
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Heterosubtypic immunity to influenza mediated by liposome adjuvanted H5N1 recombinant protein vaccines.
    Thueng-in K; Maneewatch S; Srimanote P; Songserm T; Tapchaisri P; Sookrung N; Tongtawe P; Channarong S; Chaicumpa W
    Vaccine; 2010 Sep; 28(41):6765-77. PubMed ID: 20688037
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Vaccines developed for H5 highly pathogenic avian influenza in China.
    Qiao C; Tian G; Jiang Y; Li Y; Shi J; Yu K; Chen H
    Ann N Y Acad Sci; 2006 Oct; 1081():182-92. PubMed ID: 17135510
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Report of the 6th meeting on the evaluation of pandemic influenza vaccines in clinical trials World Health Organization, Geneva, Switzerland, 17-18 February 2010.
    Girard MP; Katz J; Pervikov Y; Palkonyay L; Kieny MP
    Vaccine; 2010 Oct; 28(42):6811-20. PubMed ID: 20659520
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Generation of an attenuated H5N1 avian influenza virus vaccine with all eight genes from avian viruses.
    Shi H; Liu XF; Zhang X; Chen S; Sun L; Lu J
    Vaccine; 2007 Oct; 25(42):7379-84. PubMed ID: 17870216
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antibody persistence after 2-dose priming and booster response to a third dose of an inactivated, adjuvanted, whole-virion H5N1 vaccine.
    Lin JT; Li CG; Wang X; Su N; Liu Y; Qiu YZ; Yang M; Chen JT; Fang HH; Dong XP; Yin WD; Feng ZJ
    J Infect Dis; 2009 Jan; 199(2):184-7. PubMed ID: 19067606
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.